ERBB2 and breast cancer: In addition, in the already mentioned pooled analysis of six randomized clinical trials by the German Breast Group - GBG (in all but two trials, HER2+ BC patients received anti-HER2 therapy as part of the neoadjuvant treatment), higher TILs were associated with both DFS and increased rates of pCR after neoadjuvant chemotherapy [8].